ENZO BIOCHEM INC (ENZ)

US2941001024 - Common Stock

1.27  0 (0%)

After market: 1.21 -0.06 (-4.72%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ENZ. ENZ was compared to 116 industry peers in the Health Care Providers & Services industry. While ENZ seems to be doing ok healthwise, there are quite some concerns on its profitability. ENZ is valued expensive and it does not seem to be growing.



1

1. Profitability

1.1 Basic Checks

In the past year ENZ has reported negative net income.
In the past year ENZ has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ENZ reported negative net income in multiple years.
In multiple years ENZ reported negative operating cash flow during the last 5 years.

1.2 Ratios

ENZ has a Return On Assets (-4.62%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -6.47%, ENZ is in line with its industry, outperforming 52.59% of the companies in the same industry.
Industry RankSector Rank
ROA -4.62%
ROE -6.47%
ROIC N/A
ROA(3y)-0.19%
ROA(5y)-4.71%
ROE(3y)1.27%
ROE(5y)-8.42%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ENZ has a Gross Margin (32.87%) which is in line with its industry peers.
ENZ's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ENZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.94%
GM growth 5Y-1.52%

5

2. Health

2.1 Basic Checks

ENZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENZ has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ENZ has more shares outstanding
Compared to 1 year ago, ENZ has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -2.46, we must say that ENZ is in the distress zone and has some risk of bankruptcy.
ENZ has a worse Altman-Z score (-2.46) than 81.90% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that ENZ is not too dependend on debt financing.
ENZ has a Debt to Equity ratio of 0.05. This is amongst the best in the industry. ENZ outperforms 80.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -2.46
ROIC/WACCN/A
WACC9.81%

2.3 Liquidity

A Current Ratio of 3.20 indicates that ENZ has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.20, ENZ belongs to the top of the industry, outperforming 89.66% of the companies in the same industry.
ENZ has a Quick Ratio of 2.89. This indicates that ENZ is financially healthy and has no problem in meeting its short term obligations.
ENZ has a better Quick ratio (2.89) than 88.79% of its industry peers.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 2.89

0

3. Growth

3.1 Past

ENZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.24%, which is quite impressive.
Looking at the last year, ENZ shows a very negative growth in Revenue. The Revenue has decreased by -21.69% in the last year.
The Revenue for ENZ have been decreasing by -21.01% on average. This is quite bad
EPS 1Y (TTM)90.24%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q74.17%
Revenue 1Y (TTM)-21.69%
Revenue growth 3Y-25.79%
Revenue growth 5Y-21.01%
Revenue growth Q2Q-47.65%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

ENZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ENZ!.
Industry RankSector Rank
Dividend Yield N/A

ENZO BIOCHEM INC

NYSE:ENZ (3/28/2024, 8:07:11 PM)

After market: 1.21 -0.06 (-4.72%)

1.27

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap65.06M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.62%
ROE -6.47%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 32.87%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.2
Quick Ratio 2.89
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)90.24%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-21.69%
Revenue growth 3Y-25.79%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y